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Abstract
Background: To evaluate prognostic factors in salvage radiotherapy (RT) for patients with pre-RT prostate-specific
antigen (PSA) < 1.0 ng/ml.
Methods: Between January 2000 and December 2009, 102 patients underwent salvage RT for biochemical failure
after radical prostatectomy (RP). Re-failure of PSA after salvage RT was defined as a serum PSA value of 0.2 ng/ml
or more above the postradiotherapy nadir followed by another higher value, a continued rise in serum PSA despite
salvage RT, or initiation of systemic therapy after completion of salvage RT. Biochemical relapse-free survival (bRFS)
was estimated using the Kaplan-Meier method. Multivariate analysis was performed using the Cox proportional
hazards regression model.
Results: The median follow-up period was 44 months (range, 11-103 months). Forty-three patients experienced
PSA re-failure after salvage RT. The 4-year bRFS was 50.9% (95% confidence interval [95% CI]: 39.4-62.5%). In the
log-rank test, pT3-4 (p < 0.001) and preoperative PSA (p = 0.037) were selected as significant factors. In multivariate
analysis, only pT3-4 was a prognostic factor (hazard ratio: 3.512 [95% CI: 1.535-8.037], p = 0.001). The 4-year bRFS
rates for pT1-2 and pT3-4 were 79.2% (95% CI: 66.0-92.3%) and 31.7% (95% CI: 17.0-46.4%), respectively.
Conclusions: In patients who have received salvage RT after RP with PSA < 1.0 ng/ml, pT stage and preoperative
PSA were prognostic factors of bRFS. In particular, pT3-4 had a high risk for biochemical recurrence after salvage RT.
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Background
Radical prostatectomy (RP) is one of the curative treat-
ments for prostate cancer. However, biochemical recur-
rence after radical prostatectomy occurs in approximately
15% to 40% of patients within 5 years [1,2]. Approximately
one third of patients with biochemical recurrence will
have distant metastases, and the median actuarial period
to development of metastases following prostate-specific
antigen (PSA) elevation is 8 years [3]. Many studies have
demonstrated that salvage radiotherapy (RT) for biochem-
ical recurrence after RP is effective and enables long-term
suppression of PSA elevation [4]. Trock et al. reported
that 5- and 10-year prostate cancer-specific survival rates
were 88% and 62%, respectively, for patients with no sal-
vage treatment and 96% and 86%, respectively, for patients
who received salvage RT alone [5]. Recent studies have
suggested that early RT is more effective than delayed RT.
Some studies have demonstrated that pre-RT PSA is a
prognostic factor [4,6-14]. Based on results of those stu-
dies, it seems that pre-RT PSA < 1.0 ng/ml as a cutoff
value is a factor predicting PSA re-failure after salvage RT
[4,7,8,12], though according to a consensus panel report
published by the American Society of Therapeutic Radiol-
ogy and Oncology (ASTRO), early treatment (PSA < 1.5
ng/ml) is more successful than later treatment [15]. How-
ever, even some patients with pre-RT PSA < 1.0 ng/ml
who have received salvage RT have biochemical
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prognostic factors in salvage RT after RP for patients with
pre-RT PSA < 1.0 ng/ml.
Methods
Patients
Between January 2000 and December 2009, 102 patients
received salvage RT for biochemical failure after RP in
Tohoku University Hospital and seven affiliated hospi-
tals. Although the American Urological Association
(AUA) defines biochemical recurrence following RP as
initial serum PSA of ≥ 0.2 ng/ml with a second confir-
matory level of > 0.2 ng/ml [16], the main criterion for
salvage RT in this study was that PSA after RP was 0.1
ng/ml or more or that PSA after RP was three consecu-
tive increasing. Patients with massive local recurrence
that was detectable by CT or MRI or patients with
lymph node or distant metastasis were excluded from
this study. Patients who continued to receive hormone
therapy for PSA failure after RP but became resistant to
the hormone therapy were also excluded.
PSA doubling time
PSA doubling time (PSADT) was calculated using PSA
values above 0.1 ng/ml after RP until the start of salvage
RT. PSADT was not calculated for patients who did not
have PSA above 0.1 ng/ml. PSADT was estimated by
the natural log of 2 (0.693) divided by the slope of the
linear regression line of PSA over time [3].
Radiotherapy
The prostate bed, the bladder neck, the urethral anasto-
mosis and the seminal vesicle bed (in the case of inva-
sion to seminal vesicle) were defined as the clinical
target volume (CTV) with references to preoperative
computed tomography or magnetic resonance imaging.
The planning target volume (PTV) included the CTV
with a margin of approximately 1 cm in all directions.
The leaf margin was 0.5 cm in all directions. Salvage RT
was delivered using photon beams of 10 MV or 15 MV
mostly with the four-field technique, three-dimensional
conformal RT. The median RT dose was 64 Gy (range,
60-72 Gy). The numbers of patients receiving 60 Gy at
2 Gy daily, 62 Gy at 2 Gy daily, 64 Gy at 2 Gy daily,
64.8 Gy at 1.8 Gy daily, 70 Gy at 2 Gy daily and 72 Gy
at 1.2 Gy per fraction twice daily (hyperfractionation) to
the prostate bed were 18, 1, 67, 12, 3 and 1, respectively.
The RT dose was prescribed at the center of the PTV.
None of the patients underwent whole pelvic irradiation.
Follow-up
Re-failure of PSA after salvage RT was defined as a
serum PSA value of 0.2 ng/ml or more above the post-
radiotherapy nadir followed by another higher value, a
continued rise in serum PSA despite salvage RT, or
initiation of systemic therapy after completion of salvage
RT [17]. The time to PSA re-failure after salvage RT
was calculated from the first day of RT. Measurement of
PSA after salvage RT was done at least once every 3
months.
Statistical analysis
Biochemical relapse-free survival (bRFS) was estimated
using the Kaplan-Meier method, and the log-rank test
was used to analyze differences between patient sub-
groups categorized by prognostic variables. Multivariate
analysis was performed using the Cox proportional
hazards regression model. Hazard ratios are presented
for each prognostic factor. We evaluated pathologic
tumor (pT) stage, surgical margin, Gleason score (GS),
preoperative PSA, pre-RT PSA (Pre-RT PSA of patients
who received hormone therapy was evaluated as that
before hormone therapy.), PSADT, dose to the prostate
bed, biological effective dose (BED) (calculated using a/
b = 1.5 according to the LQ model) [18], time from RP
to the start of RT and hormonal therapy as prognostic
factors. Multivariate analysis included factors with p <
0.10 in univariate analysis. All tests were two-sided, and
statistical significance was set at the level of p < 0.05.
Statistical analysis was performed using the Statistical
Package for Social Sciences (SPSS) version 14.0 (SPSS,
Chicago, IL).
Toxicity
Complications due to salvage RT were evaluated accord-
ing to the common terminology criteria for adverse
events (CTCAE) ver.4.0. Late toxicity was defined as a
complication occurring more than three months after
salvage RT.
Ethics
Written informed consent for treatment was obtained
from all patients, and this retrospective study was per-
formed according to the principles of the Declaration of
Helsinki (2008).
Results
Patient and tumor characteristics are shown in Table 1.
Median age at salvage RT was 67 years (range, 49-81
years). Median pre-RT PSA was 0.240 (range, 0.011-
0.994 ng/ml). Median preoperative PSA was 8.8 ng/ml
(range, 1.6-120 ng/ml). Median PSADT was 6.83
months (range, 0.58-41.9 months).
Hormone therapy was given to 29 patients before and/
or during salvage RT for a median period of 6 months
(range, 1-18 months). Eleven of those patients continued
to receive hormone therapy for a median period of 12
months (range, 1-15 months) after salvage RT. Two
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stopped the therapy because of decrease in PSA but re-
started the therapy when PSA had increased again. No
patient received adjuvant hormone therapy after RP.
The median follow-up period from the start of salvage
RT was 44 months (range, 11-103 months). The 4-year
overall survival rate was 97.3% (95% confidence interval
[95% CI]: 93.6-100%). No patient died of prostate
cancer, though one patient died of esophageal cancer
and one patient died of bile duct cancer. PSA decreased
in 64 of the 73 patients who received salvage RT after
RP without hormone therapy. Forty-three patients had
re-failure after salvage RT at the last observation date.
The 4-year bRFS rate was 50.9% (95% CI: 39.4-62.5%)
(Figure 1). Multiple lung metastases occurred in one
patient 17 months after salvage RT, and bone metastases
occurred in two patients 36 and 43 months after salvage
RT.
R e s u l t so ft h el o g - r a n kt e s t sp r e s e n t e di nT a b l e2
show the 4-year bRFS for each prognostic factor before
salvage RT. It was found that pT stage (p < 0.001) and
preoperative PSA (p = 0.037) were significant prognostic
factors. The 4-year bRFS for pT1-2 and pT3-4 were
79.2% (95% CI: 66.0-92.3%) and 31.7% (95% CI: 17.0-
46.4%), respectively (Figure 2). We also analyzed bRFS
for extracapsular extension and seminal vesicle invasion.
The 4-year bRFS for positive and negative extracapsular
extension were 79.9% (95% CI: 65.4-94.5%) and 35.9%
(95% CI: 21.0-49.8%) (p = 0.003), respectively. The 4-
year bRFS for positive and negative seminal vesicle inva-
sion were 56.9% (95% CI: 44.3-71.0%) and 19.0% (95%
CI: 0-39.1%) (p = 0.004), respectively. The 4-year bRFS
for preoperative PSA < 10 ng/ml and ≥ 10 ng/ml were
62.0% (95% CI: 47.7-76.3%) and 39.3% (95% CI: 22.5-
56.0%), respectively (Figure 3). Although not significant,
PSADT (p = 0.059) and RT dose (p = 0.068) tended to
be prognostic factors. The 4-year bRFS for PSADT < 7
months and ≥ 7 months were 34.6% (95% CI: 17.5-
51.8%) and 62.2% (95% CI: 46.7-77.7%), respectively
Table 1 Patients’ characteristics
Characteristic No. Median (range)
















Preoperative PSA (ng/ml) 8.8 (1.6-120)
<1 0 5 8
≥ 10 44
Pre-RT PSA (ng/ml) 0.240 (0.011-0.994)
< 0.25 52
≥ 0.25 50




RT dose (Gy) (BED, a/b = 1.5) 64 (149.3) (60-72 [129.6-
163.3])
60 at 2 daily (140.0) 18
62 at 2 daily (144.7) 1
64 at 2 daily (149.3) 67
64.8 at 1.8 daily (142.6) 12
70 at 2 daily (163.3) 3
72 at 1.2 per fraction twice daily (HF)
(129.6)
1
Time from RP to RT (months) 21 (5-99)





Abbreviations: RT = radiotherapy, PSA = prostate-specific antigen, BED =
biological effective dose, HF = hyperfractionation, RP = radical prostatectomy
Figure 1 Biochemical relapse-free survival (bRFS) after salvage
radiotherapy.
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Gy were 36.8% (95% CI: 15.2-58.5%) and 52.7% (95% CI:
39.5-69.1%), respectively (Figure 5). When we evaluated
bRFS in 73 patients without hormone therapy, pT stage
(p < 0.001) and preoperative PSA (p = 0.018) were also
significant prognostic factors. In those patients, the 4-
year bRFS for pT1-2 and pT3-4 were 78.5% (95% CI:
62.9-94.2%) and 29.6% (95% CI: 13.7-45.6%), respec-
tively, and the 4-year bRFS for preoperative PSA < 10
ng/ml and ≥ 10 ng/ml were 64.0% (95% CI: 48.5-79.5%)
and 33.9% (95% CI: 14.3-53.6%), respectively.
In 79 patients who received 64 or 64.8 Gy to the pros-
tate bed, the 4-year bRFS for pT1-2 and pT3-4 were
85.5% (95% CI: 73.6-97.3%) and 28.8% (95% CI: 7.87-
49.8%) (p < 0.001), respectively (Figure 6).
Multivariate analysis was evaluated by pT stage, preo-
perative PSA, PSADT and RT dose. Only pT stage was
a significant prognostic factor (p = 0.003) and the
hazard ratio (HR) with pT3-4 was 3.512 (95% CI: 1.535-
8.037) (Table 3). After adjusting for pT, none of the
other variables retained prognostic significance.
Grade 2 late urinary tract complication was observed
in one patient who suffered from urinary occlusion.
Grade 3 late rectal complication was observed in one
patient who suffered from rectal bleeding.
Discussion
Moreira et al. reported that the 1-, 3- and 5-year risks of
receiving any salvage treatment after RP were 29%, 48%
Table 2 Results of log-rank tests
Factor 4-year bRFS (%) (95% CI) p value







≤ 7 58.9 (44.5-73.3)
≥ 8 35.2 (14.7-51.5)
Preoperative PSA (ng/ml) 0.037
< 10 62.0 (47.7-76.3)
≥ 10 39.3 (22.5-56.0)
Pre-RT PSA (ng/ml) 0.620
< 0.25 54.5 (37.5-71.6)
≥ 0.25 45.9 (30.2-64.9)
PSA doubling time (months) 0.059
< 7 34.6 (17.5-51.8)
≥ 7 62.2 (46.7-77.7)
RT dose (Gy) 0.068
< 64 36.8 (15.2-58.5)
≥ 64 51.7 (37.6-65.9)
BED (Gy) (a/b = 1.5) 0.213
< 145 41.4 (23.5-59.3)
≥ 145 54.3 (39.5-69.1)
Time from RP to RT (months) 0.310
< 24 45.2 (29.1-61.4)
≥ 24 57.4 (40.9-73.9)
Hormone therapy 0.627
Done 50.5 (20.2-72.9)
Not done 50.7 (37.6-63.7)
Abbreviations: bRFS = biochemical relapse-free survival, RT = radiotherapy,
PSA = prostate-specific antigen, BED = biological effective dose, RP = radical
prostatectomy, CI = confidence interval
Figure 2 Four-year biochemical relapse-free survival in patients
with pT3-4 and that in patients with pT1-2.
Figure 3 Four-year biochemical relapse-free survival in patients
with preoperative prostate-specific antigen (PSA) ≥ 10 ng/ml
and that in patients with preoperative PSA < 10 ng/ml.
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major treatments for biochemical recurrence after RP,
and many studies have shown that salvage RT is effec-
tive [4,6-14,20-27]. In our study, PSA decreased in 64 of
the 73 patients who received salvage RT after RP with-
out hormone therapy, suggesting that this treatment was
effective for biochemical failure after RP. Those patients
might have had at least a component local disease. PSA
did not decrease in the patient who had multiple lung
metastases. Although comparison with results of
previous studies might not be appropriate differences in
race, conditions under which salvage RT was performed
and criteria of re-failure after salvage RT, bRFS in the
present study was similar to that in previous studies
(Table 4). However, significant prognostic factors for re-
failure of salvage RT in those studies were different.
Some of those studies showed that pre-RT PSA < 1.0
n g / m lw a sap r o g n o s t i cf a c t o r [4,7,8,12]. In those stu-
dies, median values of pre-RT PSA were higher (0.7-4.5
ng/ml) than that in the present study (0.240 ng/ml).
However, even some patients with pre-RT PSA < 1.0
ng/ml who have received salvage RT experience bio-
chemical recurrence. Therefore, we retrospectively eval-
uated prognostic factors in salvage RT for patients with
pre-RT PSA < 1.0 ng/ml.
Figure 5 Four-year biochemical relapse-free survival in patients
with radiotherapy (RT) dose ≥ 64 Gy and that in patients with
RT dose < 64 Gy.
Figure 6 Four-year biochemical relapse-free survival for pT3-4
and that for pT1-2 in patients who received 64 or 64.8 Gy to
the prostate bed.
Table 3 Multivariate analysis of parameters with bRFS
Factors Hazards ratio (95% CI) p value
Pathologic tumor stage 0.003
T1-2 Reference
T3-4 3.512 (1.535-8.037)
Preoperative PSA (ng/ml) 0.177
< 10 Reference
≥ 10 1.566 (0.816-3.006)
PSADT (months) 0.272
< 7 Reference
≥ 7 0.686 (0.350-1.344)
RT dose (Gy) 0.357
< 64 Reference
≥ 64 0.712 (0.345-1.469)
Abbreviations: bRFS = biochemical relapse-free survival, PSA = prostate-
specific antigen, PSADT = prostate-specific antigen doubling time, RT =
radiotherapy, RP = radical prostatectomy, CI = confidence interval
Figure 4 Four-year biochemical relapse-free survival in patients
with prostate specific-antigen doubling time (PSADT) ≥ 7
months and that in patients with PSADT < 7 months.
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factor. Therefore, there might be no need for early sal-
vage RT in patients with pre-RT PSA < 1.0 ng/ml. How-
ever, early or more intense salvage RT in cases of high
risk for recurrence (e.g., pT3-4 and preoperative PSA >
10 ng/ml) even with PSA < 1.0 ng/ml might be neces-
sary because the rate of biochemical recurrence after
salvage RT is relatively high even in patients with pre-
RT PSA < 1.0 ng/ml. Further investigation of the prog-
nostic factors of salvage RT other than pre-RT PSA in
patients with high risk for recurrence is needed.
Recently, PSADT has been utilized as a prognostic
factor for prostatectomy. Pound et al. found that
PSADT predicted the likelihood of subsequent develop-
ment of metastatic disease [3]. Freedland et al. found
that prostate cancer-specific survival of patients with
PSADT < 9 months (especially < 3 months) was worse
than that of patients with PSADT > 15 months [28].
Some past studies have demonstrated that PSADT was
also a prognostic factor of salvage RT [6,22,24,27]. Med-
ian pre-RT PSA in some of those studies was 1.0 ng/ml
or less. In a study by Trock et al. with median pre-RT
PSA < 1.0 ng/ml, salvage RT performed within 2 years
after biochemical recurrence significantly improved
prostate cancer-specific survival among patients with
PSADT of less than 6 months (HR: 0.14) [5]. Although
not significant in our study, the 4-year bRFS rate of
patients with PSADT < 7 months was worse than that
of patients with PSADT ≥ 7 months. The reason why
PSADT was not a significant factor in our study might
be that there were 16 patients for whom PSADT data
were not available and the number of cases for analysis
was insufficient. If pre-RT PSA is < 1.0 ng/ml, we might
be able to refer to PSADT for starting salvage RT.
Although PSADT is widely used to predict outcomes
such as time to progression, underlying the impressive
evidence of predictive value and prognostic value of
PSADT are many basic questions about how it should
be calculated [29]. Although Arlen et al. demonstrated
that PSA kinetics was all calculated from the point of
failure of 0.2 ng/ml [30], PSADT was calculated using
PSA values above 0.1 ng/ml after RP in our study.
In our study, only pT3-4 was a significant factor pre-
dicting PSA re-failure after salvage RT in multivariate
analysis. In a study by Wiegel et al., bRFS for pT3-4 was
w o r s et h a nt h a tf o rp T 2( p=0 . 0 4 7 )[ 2 6 ] .A l t h o u g h
bRFS for pT3-4 was poor in patients with PSA < 1.0 ng/
ml, there may be some room for improvement in RT
for patients with pT3-4. One method for improving
bRFS in patients with pT3-4 is postoperative RT.
According to the European Organization for Research
and Treatment of Cancer (EORTC) 22911, adjuvant
external irradiation after radical prostatectomy improves
biochemical progression-free survival and local control
in patients with positive margins [31]. In that study, the
5-year biochemical progression-free survival rates for
patients in the Irradiation group and the Wait and see
group with one or more pathological risk factors (cap-
sule perforation, positive surgical margins and invasion
of seminal vesicles) were 74.0% and 52.6%, respectively.
Table 4 Past studies on salvage RT for biochemical recurrence after RP
Study Patients (n) Median pre-RT PSA (ng/ml) prognostic factors after salvage RT bRDS(%)
Hagan et al [7] 91 4.5 pre-RT PSA (< 1.0 ng/ml) 55 (5-year)
Quero et al [8] 59 1.43 pre-RT PSA (< 1.0 ng/ml) 41.2 (5-year)
Macdonald et al [9] 121 1.4 pre-RT PSA (< 0.2 ng/ml) NA
Anscher et al [10] 89 1.4 pre-RT PSA (< 2.5 ng/ml), RT dose (> 65 Gy) 50 (4-year)
Chawla et al [20] 54 1.3 Gleason score (≤ 6), time to detectable postoperative PSA 35 (5-year)
Tsien et al [21] 57 1.2 Gleason score (< or = 7) 58 (5-year)
Neuhof et al [4] 171 1.1 Gleason score (< 7), pre-RT PSA (< 1.0 ng/ml) 35.1 (5-year)
Jacinto et al [22] 43 0.87 PSADT (> 4.0 months) 71 (3-year)
Taylor et al [23] 66 0.8 delayed rise in PSA after RP 66 (5-year)
Pazona et al [11] 307 0.8 pre-RT PSA (< 1.3 ng/ml), Seminal vesicle 40 (5-year)
Stephenson et al [6] 501 0.72 Gleason score (≤ 7), pre-RT PSA (≤ 2.0 ng/ml),
PSADT (> 10 months)
45 (4-year)
Buskirk et al [12] 368 0.7 pT2-3a, Gleason score (≤ 7), Pre-RT PSA (< 1.0 ng/ml) 46 (5-year)
Bernard et al [13] 364 0.6 RT dose (> 66.6 Gy, patients with pre-RT PSA < 0.6 ng/ml) 50 (5-year)
Ward et al [24] 211 0.6 PSADT (> 12 months) 34 (10-year)
King et al [25] 37 0.49 PSAV (≤ 1.0 ng/ml/year) NA
Wiegel et al [26] 162 0.33 PSA undetectable after salvage RT (< 0.1 ng/ml) 54 (3.5-year)
Tomita et al [27] 51 0.25 PSADT (> 3.0 months), Gleason Score, RT dose (≥ 60 Gy) 55.1 (3-year)
Terai et al [14] 37 0.146 cT1-2, pT2, pre-RT PSA (> 0.15 ng/ml) 54 (5-year)
Abbreviations: RT = radiotherapy, RP = radical prostatectomy, PSA = prostate-specific antigen, bRDS = biochemical relapse-free survival, PSADT = PSA doubling
time, PSAV = PSA velocity, NA = not available
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vant radiotherapy for patients with pT3 after RP
resulted in significant reduction of the risk for PSA
relapse (median PSA relapse-free survival: 10.3 years for
radiotherapy vs. 3.1 years for observation) [32]. In their
further study, metastasis-free survival was significantly
greater with adjuvant radiotherapy (93 of 214 patients
on the radiotherapy arm vs 114 of 211 patients on the
observation arm) and survival improved significantly
with adjuvant radiotherapy (88 deaths in 214 patients on
the radiotherapy arm vs 110 deaths in 211 patients on
the observation arm) [33]. In a study by Jereczek-Fossa
et al., failure-free survival of postoperative RT patients
was significantly longer than that of patients who had
undergone salvage RT (4-year biochemical control rates:
81.7% and 60.5%, respectively) [34]. Postoperative RT
was suggested to be more effective than salvage RT in
patients with pT3-4. The reason why bRFS for patients
with pT3-4 is poor may also be that these patients
already have latent lymph node metastases. Spiotto et al.
reported that whole pelvic RT resulted in superior bRFS
compared with prostate bed RT, especially in high-risk
patients with GS ≥ 8, preoperative PSA > 20 ng/ml,
pT3, or pathologic lymph node involvement (5-year
bRFS: 47% vs 21%) [35]. Whole pelvic RT might also be
an effective treatment.
The ASTRO consensus guidelines suggest a minimum
of 64 Gy at conventional dose fractionation [15]. In our
study, bRFS of patients treated with a dose ≥ 64 Gy
tended to be better than that of patients treated with a
dose < 64 Gy (51.7% [95% CI: 38.5-67.0%] vs. 36.8%
[95% CI: 15.2-58.5%], p = 0.068). At least 64 Gy may be
required for salvage RT after RP. King et al. found that
salvage RT with 70 Gy was superior to that with 60 Gy
(5-year bRFS: 58% vs. 25%) [36]. Bernard et al. found
that doses higher than 66.6 Gy resulted in decreased
risk of biochemical failure after salvage RT [13]. King et
al. reported that the dose-response relationships of sal-
vage RT and definitive external beam radiotherapy for
localized prostate cancer were similar [37]. Only in
patients treated with 64 or 64.8 Gy, the 4-year bRFS for
patients with pT3-4 was much worse than that for
patients with pT1-2 (85.5% [95% CI: 73.6-97.3%] and
28.8% [95% CI: 7.87-49.8%], respectively, p < 0.001),
(Figure 6). This result suggested that 64 Gy in patients
with pT3-4 might be insufficient. The results of a study
by Cozzarini et al. provided strong support for the use
of RT at doses ≥ 70 Gy in pT3-4 patients [38]. There-
fore, patients with pT3-4 might need dose escalation for
salvage RT after RP.
T h e r ew e r es o m el i m i t a t i o n si nt h ep r e s e n ts t u d y .
First, data for patients who received hormone therapy
prior to RT may confound the analysis and lessen the
significance of some risk factors. The value of PSA is
strongly affected by hormone therapy. Therefore, we
also evaluated bRFS in 73 patients without hormone
therapy. Although the number of samples became small,
the result was similar. Second, we analyzed bRFS in the
present study retrospectively, and there were two sepa-
rate definitions of the criterion for salvage RT. The cri-
teria were slightly different between previous studies.
AUA defines biochemical recurrence following RP as
initial serum PSA of ≥ 0.2 ng/ml with a second confir-
matory level of > 0.2 ng/ml [16]. We analyzed bRFS in
65 patients with pre-PSA of ≥ 0.2 ng/ml. The results
showed that only pT was only a siginificant prognostic
factor (p < 0.001). The bRFS after salvage RT might be
affected by pT3-4 after all, even if we consider those
limitations.
Conclusion
Salvage RT is an effective treatment for patients with
biochemical recurrence after RP. In patients with PSA <
1.0 ng/ml, pT stage and preoperative PSA were prog-
nostic factors of bRFS. In particular, pT3-4 had a high
risk for biochemical recurrence after salvage RT, and
more intense treatment is recommended for such
patients.
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